Cell-free DNA testing for early hepatocellular carcinoma surveillanceResearch in context

Autor: Lei Chen, Tong Wu, Rong Fan, Yun-Song Qian, Jing-Feng Liu, Jian Bai, Bo Zheng, Xiao-Long Liu, Dan Zheng, Lu-Tao Du, Guo-Qing Jiang, Ying-Chao Wang, Xiao-Tang Fan, Guo-Hong Deng, Chun-Ying Wang, Feng Shen, He-Ping Hu, Qing-Zheng Zhang, Yi-Nong Ye, Jing Zhang, Yan-Hang Gao, Jie Xia, Hua-Dong Yan, Min-Feng Liang, Yan-Long Yu, Fu-Ming Sun, Yu-Jing Gao, Jian Sun, Chun-Xiu Zhong, Yin Wang, Hui Wang, Fei Kong, Jin-Ming Chen, Hao Wen, Bo-Ming Wu, Chuan-Xin Wang, Lin Wu, Jin-Lin Hou, Hong-Yang Wang
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: EBioMedicine, Vol 100, Iss , Pp 104962- (2024)
Druh dokumentu: article
ISSN: 2352-3964
DOI: 10.1016/j.ebiom.2023.104962
Popis: Summary: Background: Liver cirrhosis (LC) is the highest risk factor for hepatocellular carcinoma (HCC) development worldwide. The efficacy of the guideline-recommended surveillance methods for patients with LC remains unpromising. Methods: A total of 4367 LCs not previously known to have HCC and 510 HCCs from 16 hospitals across 11 provinces of China were recruited in this multi-center, large-scale, cross-sectional study. Participants were divided into Stage Ⅰ cohort (510 HCCs and 2074 LCs) and Stage Ⅱ cohort (2293 LCs) according to their enrollment time and underwent Tri-phasic CT/enhanced MRI, US, AFP, and cell-free DNA (cfDNA). A screening model called PreCar Score was established based on five features of cfDNA using Stage Ⅰ cohort. Surveillance performance of PreCar Score alone or in combination with US/AFP was evaluated in Stage Ⅱ cohort. Findings: PreCar Score showed a significantly higher sensitivity for the detection of early/very early HCC (Barcelona stage A/0) in contrast to US (sensitivity of 51.32% [95% CI: 39.66%–62.84%] at 95.53% [95% CI: 94.62%–96.38%] specificity for PreCar Score; sensitivity of 23.68% [95% CI: 14.99%–35.07%] at 99.37% [95% CI: 98.91%–99.64%] specificity for US) (P
Databáze: Directory of Open Access Journals